NSNerea Sanchez

Nerea Sanchez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nerea Sanchez has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    New technologies in oral reconstructive medicine: Consensus report of the AAP/OF/SEPA Workshop

    by Mariano Sanz, Sašo Ivanovski, José Nart, Frank Schwarz, Hom‐Lay Wang, Tara L. Aghaloo, Bilal Al‐Nawas, Gustavo Avila‐Ortiz, Shayan Barootchi, Juan Blanco, et al.

    Background: The objectives of this Workshop were to evaluate the efficacy of scaffolding technologies for horizontal and vertical ridge augmentation; to evaluate the efficacy of substitute scaffolds for soft tissue augmentation in the context of implant therapy; to evaluate the efficacy of cells and/or biologics combined with scaffolds for alveolar bone regeneration; to evaluate the efficacy of cells and/or biologics combined with scaffolds for soft tissue regeneration in the context of implant therapy; and to evaluate emerging technologies and personalized strategies for improving hard and/or soft tissue defects around natural teeth and dental implants. Methods: The Workshop discussions were informed by five specifically commissioned systematic reviews from the following three Working Groups: Working Group 1 – Use of scaffolds for bone and soft tissue regeneration; Working Group 2 – Use of cells and/or biologics combined with scaffolds for hard and soft tissue regeneration; and Working Group 3 – Current, emerging, and personalized approaches for periodontal and peri‐implant tissue regeneration. The Workshop participants were informed by the compiled evidence from the five systematic reviews within each Working Group to address pertinent issues to inform clinical practice, research, and the public community. Results: The consensus among the Workshop group participants was that cellular therapies and biologics, alone and in combination with scaffolding technologies, offer strong potential in regenerating tissues around teeth and dental implants. There was variability in treatment outcomes depending on the overall evidence and the efficacy of these technologies, as well as on the specific defects and patient‐based constraints. The consensus report detailed the results and implications of the findings, demonstrating the value of these technologies in improving clinical and patient‐reported outcomes. Conclusions: Current regenerative approaches lead to long‐term stable outcomes at natural teeth as well as dental implant sites; novel technologies can benefit patients by enhancing longer‐term stability of teeth and implants to promote the health of the oral cavity and dentition; and artificial intelligence–enabled modeling can contribute to the identification of relevant features at the individual (as opposed to population) level, empowering patients to be active participants in their journeys and improving science‐to‐public communication.

  • Open Access

    Use of cells and/or biologics combined with scaffolds for soft tissue regeneration around dental implants

    by Eduardo Montero, Zhaozhao Chen, Nerea Sánchez, Javier Sanz Esporrin, Hom‐Lay Wang, George A. Mandelaris

    Background: The aim of this systematic review is to evaluate the efficacy of cell‐based therapies and biologically enhanced scaffolds for peri‐implant soft tissue regeneration, including the increase in soft tissue thickness (STT) and/or keratinized mucosa (KM) augmentation. Methods: A systematic literature search was conducted in Ovid MEDLINE, EMBASE, and Dentistry and Oral Sciences Source until August 2025. A focused question was developed: “In patients with soft tissue defects requiring soft tissue augmentation procedures prior to, at the time of implant placement or after it, what is the efficacy of combining cell therapy and/or biological treatments with a soft tissue scaffold compared to the use a soft tissue scaffold without cells and/or biologics, or no scaffold, on the increase of STT and/or KM in clinical trials or prospective case series?”. Post‐operative morbidity, interproximal bone level changes, clinical peri‐implant outcomes or patient‐reported outcome measures (PROMs) were collected. Risk of bias was assessed using RoB 2.0, ROBINS‐I and the National Institutes of Health (NIH) Study Quality Assessment Tool. Results: Ten publications were included (six randomized clinical trials [RCTs] and four prospective case series). The use of free gingival grafts (FGGs) lead to significantly greater KM augmentation when compared with platelet‐rich fibrin (PRF) membranes (weighted mean difference [WMD] = −2.0; 95% confidence interval [CI]: −3.3, −0.8; p < 0.001) although PRF membranes significantly increased the amount of KM when compared to no scaffold/graft ( n = 2; WMD = 1.1 mm; 95% CI: 0.2, 2.1; p = 0.017) and seem to increase also STT. Available data on other biologics (e.g., recombinant human platelet‐derived growth factor BB [rhPDGF‐BB]) are scarce. No studies evaluating cell therapies were identified. Conclusions: PRF membranes are effective in increasing the KM and STT around dental implants, even if KM augmentation by means of autogenous grafts lead to superior outcomes. There is a lack of evidence on cell‐based therapies or other biologics for their use in soft tissue regeneration around dental implants.

  • Management of Acute Periodontal Conditions—The EFP S2k Level Clinical Practice Guideline

    by David Herrera, Panos N. Papapanou, Iain Chapple, Moritz Kebschull, Wim Teughels, Maurizio S. Tonetti, Mariano Sanz, Anton Sculean, Mario Aimetti, Ivan Alajbeg, et al.

    Background: The European Federation of Periodontology (EFP) has developed Clinical Practice Guidelines (CPGs) for the treatment of periodontitis and for the management of peri‐implant diseases. In accordance with the 2018 Classification, acute periodontal conditions are characterised by rapid‐onset pain or discomfort, tissue destruction and infection. Therefore, the development of a CPG to guide patients and clinicians in their management is justified. Aim: To develop an S2k‐level CPG for the management of acute periodontal conditions, necrotising periodontal diseases, periodontal abscesses and acute manifestations of endodontic–periodontal lesions. Methods: This S2k‐level CPG was developed by the EFP, following methodological guidance from the Association of Scientific Medical Societies in Germany and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) process. A rigorous and transparent process included synthesis of relevant research in two commissioned systematic reviews, evaluation of the quality and strength of evidence, formulation of specific recommendations and a structured consensus process involving leading experts and a broad base of stakeholders. Recommendations were based on the best available evidence, combined with structured expert consensus, particularly in areas where direct evidence remains scarce. Results: The S2k‐level CPG for the management of acute periodontal conditions presents a structured approach, grouping the recommendations in three successive steps: (1) confirming diagnosis, following the case definitions of the 2018 classification; (2) initial treatment, to control the acute condition including pain and active tissue destruction; and (3) subsequent treatments, to manage the pre‐existing conditions and prevent the risk of disease recurrence and/or control the potential sequelae. Conclusion: The present S2k‐level CPG informs clinical practice, health systems, policymakers and, indirectly, the public on the available and most effective interventions in the management of acute periodontal conditions.


  • Management of Necrotising Periodontal Diseases: A Systematic Review

    by Eduardo Montero, Nerea Sánchez, Evangelia P. Zampa, Bettina Alonso, Marion Arce, Phoebus Madianos

    Aim: To evaluate the efficacy of interventions for treating necrotising periodontal diseases (NPDs), including the management of the acute condition and subsequent therapies targeting sequelae and/or predisposing factors. Methods: Following PRISMA guidelines, electronic and manual searches were conducted up to April 2025. Randomised controlled trials (RCTs), controlled clinical trials (CCTs) and case series assessing any therapeutic intervention for NPDs (separating them for acute disease resolution and treatment of the preexisting condition and/or management of sequelae) were included. Results: Thirty‐five studies were included (18 RCTs, 2 CCTs, 15 case series). Mechanical debridement combined with antiseptic rinses (e.g., chlorhexidine or hydrogen peroxide) constitutes the primary therapeutic approach. Systemic antimicrobials, mainly metronidazole, have also frequently been evaluated and used as adjuncts or monotherapy. Reduced pain, bleeding and ulcer resolution within days were the common findings for all tested interventions. Recent trials explored photodynamic therapy (PDT) as adjuncts, showing short‐term clinical and microbiological benefits. Evidence was heterogeneous and of high risk of bias. Only five studies addressed post‐acute management, with none of them investigating reconstructive approaches or long‐term recurrence prevention. Conclusions: Management of NPDs relies primarily on mechanical debridement and antiseptics, with systemic antimicrobials reserved for cases with systemic involvement. Adjunctive modalities such as PDT have shown promising results but require further validation. Evidence on reconstructive approaches and recurrence prevention is lacking.


  • Open Access

    Bone Augmentation of Atrophic Alveolar Ridges Using a Synthetic Bone Substitute With Mesenchymal Stem Cells: A Randomized, Controlled Clinical Trial

    by Mariano Sanz, Cecilie Gjerde, Bjørn Tore Gjertsen, Alberto Ortiz‐Vigón, Nerea Sanchez, Alain Hoornaert, Jordi Caballe‐Serrano, Maria Giralt‐Hernando, Frederick Gaultier, Nicoleta Reinald, et al.

    Objectives: To assess the efficacy and safety of a cell‐based therapy for 3D bone augmentation of severe alveolar bone defects prior to dental implant placement. Materials and Methods: A Phase 2 randomized controlled clinical trial evaluated the safety and efficacy of a cell therapy using expanded autologous iliac crest‐derived mesenchymal cells seeded on a synthetic bioabsorbable bone substitute covered with a non‐resorbable membrane. The control group received an autogenous bone block graft. After 5 months, CBCT scans were compared to measure the bone volume changes achieved after the regenerative surgery. Subsequently, dental implants were placed in the regenerated areas. Results: A total of 48 patients were included and randomized (36 patients in the test group and 12 in the control group). However, seven patients did not reach the minimum required number of expanded MSCs and were therefore unable to be treated. The tested intervention demonstrated significantly greater gains in bone volume, with a mean difference of 480.01 mm 3 ( p = 0.032). Similarly, the mean change in bone crest volume from baseline to 5 months was notably higher in the test group (1066.91 mm 3 ) compared to the control group (586.9 mm 3 ). Adverse reactions and patient morbidity were minor in both groups. Implants were placed on the regenerated bone, and all were integrated successfully in both groups. Conclusions: The cell‐based therapy resulted in significant changes in bone volume compared to the control treatment, enabling dental implants in all patients. The procedure was associated with minimal adverse effects and patient morbidity. Trial Registration: ClinicalTrials.gov : NCT03373052, NCT04297813


  • Open Access

    Cell Therapy for Periodontal, Soft‐Tissue, and Craniofacial Regeneration

    by Kamal Mustafa, Shuntaro Yamada, Nerea Sanchez, Magdalena Mayol, Cecilie Gjerde, Mariano Sanz

    Periodontal and craniofacial regeneration presents significant challenges owing to the complex tissue architecture, inadequate vascularization, and diminished stem cell populations within damaged tissues. Traditionally, autologous bone grafts or alternative bone substitute materials have been employed to address these conditions; however, these approaches are constrained by donor site morbidity, limited availability, and suboptimal regenerative efficacy. The advancement of mesenchymal stem/stromal cell (MSC) biology has accelerated the development of cell‐based therapies in modern dentistry, which now focuses on biologically driven approaches to regenerate tissues. MSC‐based therapies currently under investigation, both preclinically and clinically, show promise for improving tissue integration and healing processes of both soft and hard tissues, attributable to their multipotent nature, immunomodulatory properties, and paracrine signaling capabilities. Nevertheless, obstacles persist, including inconsistent standardization, limited scalability, regulatory hurdles, a paucity of controlled studies, and restricted biomaterial options. This review evaluates MSC‐based treatments for periodontal and craniofacial reconstruction by discussing recent research findings and existing obstacles. This review also examines future prospects, such as advanced biofabrication methods, including 3D printing and bioprinting, which have the potential to improve personalized cell therapy for periodontal and craniofacial regeneration.


  • Top Cited Papers
    Open Access

    Consensus Report of the 20th European Workshop on Periodontology: Contemporary and Emerging Technologies in Periodontal Diagnosis

    by David Herrera, Maurizio S. Tonetti, Iain Chapple, Moritz Kebschull, Panos N. Papapanou, Anton Sculean, Loreto Abusleme, Mario Aimetti, Georgios Belibasakis, Juan Blanco, et al.

    Background: This Consensus Workshop dealt with diagnostic methodologies in the context of surveillance, screening, assessment of stage and grade, prognosis, monitoring and prediction of periodontal status. Several elements provided the impetus for the workshop, including the limited quality of available research on diagnostic tests, the rapid development of new technologies, the implementation of the 2018 classification and the declarations of the World Health Organisation on diagnosis and oral health. Aim: To update and evaluate the evidence on diagnostic methods, considering recent advances in knowledge and the implementation of the 2018 classification. Methods: The European Workshop Committee of the European Federation of Periodontology guided the development of a consensus report after commissioning eight systematic reviews within three working groups. The reviews were discussed during the in‐person consensus meeting involving 70 participants from 21 different countries. Results: Working Group 1 discussed innovations in traditional diagnostic approaches, justified manual probing as the reference standard and assessed the value of image‐based methods. Working Group 2 analysed diagnostic tests based on microbial and host biomarkers and genetic diagnostic tests. Working Group 3 covered emerging technologies to be used within dental and non‐dental clinical settings, focusing principally on the impact of questionnaire‐based assessments and artificial intelligence systems (AIS) in interpreting different data modalities. Conclusion: Although manual periodontal probing is firmly established as the reference standard, additional approaches based on imaging, biomarkers, host genetics, questionnaires and the development of emerging applied data science methods (e.g., AIS) are increasingly integrated in periodontal diagnostics.


  • Open Access

    Effect of peri‐implant mucosal thickness on esthetic outcomes and the efficacy of soft tissue augmentation procedures: Consensus report of group 2 of the SEPA/DGI/OF workshop

    by Ronald E. Jung, Kathrin Becker, Stefan P. Bienz, Christer Dahlin, Nikos Donos, Christian Hammächer, Gerhard Iglhaut, Antonio Liñares, Alberto Ortiz‐Vigón, Nerea Sanchez, et al.

    Objectives: The aim of this study was to comprehensively assess the literature in terms of the effect of peri‐implant mucosal thickness on esthetic outcomes and the efficacy of soft tissue augmentation procedures to increase the mucosal thickness with autogenous grafts or soft tissue substitutes.Material and methods: Two systematic reviews (SR) were performed prior to the consensus meeting to assess the following questions. Review 1, focused question: In systemically healthy patients with an implant‐supported fixed prosthesis, what is the influence of thin as compared to thick peri‐implant mucosa on esthetic outcomes? Review 2, focused question 1: In systemically healthy humans with at least one dental implant (immediate or staged implant), what is the efficacy of connective tissue graft (CTG), as compared to absence of a soft tissue grafting procedure, in terms of gain in peri‐implant soft tissue thickness (STT) reported by randomized controlled clinical trials (RCTs) or controlled clinical trials (CCTs)? Review 2, focused question 2: In systemically healthy humans with at least one dental implant (immediate or staged implant), what is the efficacy of CTG, as compared to soft tissue substitutes, in terms of gain in peri‐implant STT reported by RCTs or CCTs? The outcomes of the two SRs, the consensus statements, the clinical implications, and the research recommendations were discussed and subsequently approved at the consensus meeting during the group and plenary sessions.Conclusions: There was a tendency of superior esthetic outcomes in the presence of a thick mucosa. The connective tissue graft remains the standard of care in terms of increasing mucosa thickness.


  • Open Access

    Cell Therapy Based on Gingiva-Derived Mesenchymal Stem Cells Seeded in a Xenogeneic Collagen Matrix for Root Coverage of RT1 Gingival Lesions: An In Vivo Experimental Study

    by Nerea Sanchez, Fabio Vignoletti, Ignacio Sanz-Martin, Alejandro Coca, Javier Nuñez, Estela Maldonado, Javier Sanz-Esporrin, Irene Hernando-Pradíes, Silvia Santamaría, David Herrera, et al.

    (1) Background: To investigate the effect of a xenogeneic collagen matrix (CMX) seeded with autologous gingiva-derived mesenchymal cells (GMSCs) when combined with a coronally advanced flap (CAF) in the treatment of localized gingival recession type 1 (RT1). (2) Methods: Dehiscence-type defects were created in seven dogs. GMSCs were isolated, transfected with a vector carrying green fluorescent protein (GFP) and expanded. Once chronified, the defects were randomly treated with (1) CAF plus the combination of CMX and GFP+ GMSCs, (2) CAF plus CMX with autologous fibroblasts, (3) CAF plus CMX and (4) CAF alone. Histological and clinical outcomes at 2- and 6-week healing periods were analyzed and compared among groups. (3) Results: Histologically, the addition of autologous cells to the CMX resulted in reduced inflammation and a variable degree of new cementum/bone formation. CMX plus GMSCs resulted in greater mean recession reduction (1.42; SD = 1.88 mm) and percentage of teeth with recession reduction of ≥2 mm (57%) when compared to the other groups, although these differences were not statistically significant. (4) Conclusions: The histometric and clinical results indicated a positive trend favouring the combination of CMX and GMSCs with the CAF when compared to the groups without cells, although these differences were not statistically significant.


  • Open Access

    Periodontal bioengineering with mesenchymal stem cells

    by Nerea Sanchez, Mariano Sanz

    Plastic and Aesthetic Research is an open acccess journal, which publishes articles on technical and clinical studies related to plastic and aesthetic surgery.